APA (7th ed.) Citation

Karagiannis, P., Singer, J., Hunt, J., Gan, S. K. E., Rudman, S. M., Mechtcheriakova, D., . . . Karagiannis, S. N. (2009). Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/ neu-positive tumour cells. Cancer Immunology, Immunotherapy, 58(6), 915. https://doi.org/10.1007/s00262-008-0607-1

Chicago Style (17th ed.) Citation

Karagiannis, Panagiotis, et al. "Characterisation of an Engineered Trastuzumab IgE Antibody and Effector Cell Mechanisms Targeting HER2/ Neu-positive Tumour Cells." Cancer Immunology, Immunotherapy 58, no. 6 (2009): 915. https://doi.org/10.1007/s00262-008-0607-1.

MLA (9th ed.) Citation

Karagiannis, Panagiotis, et al. "Characterisation of an Engineered Trastuzumab IgE Antibody and Effector Cell Mechanisms Targeting HER2/ Neu-positive Tumour Cells." Cancer Immunology, Immunotherapy, vol. 58, no. 6, 2009, p. 915, https://doi.org/10.1007/s00262-008-0607-1.